

Amye J Tevaarwerk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6265607/publications.pdf>

Version: 2024-02-01

107
papers

2,812
citations

196777

29
h-index

223390

49
g-index

107
all docs

107
docs citations

107
times ranked

5262
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of Engineering, Primary Care, Oncology Collaborative Regarding a Survey of Primary Care on a Re-Engineered Survivorship Care Plan. Journal of Cancer Education, 2022, 37, 23-29.	0.6	5
2	Barriers and facilitators to the use of survivorship care plans by hematopoietic stem cell transplant survivors and clinicians. Supportive Care in Cancer, 2022, 30, 1323-1330.	1.0	1
3	Usage of a Web-Based Workplace and Symptom Self-Management Intervention Tool to Improve Work Ability for Breast Cancer Survivors. Journal of Cancer Education, 2022, 37, 1824-1833.	0.6	2
4	The current status of survivorship care provision at the state level: a Wisconsin-based assessment. Journal of Cancer Survivorship, 2022, 16, 1355-1365.	1.5	1
5	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). Journal of Clinical Oncology, 2022, 40, 978-987.	0.8	86
6	Unmet needs and problems related to employment and working as reported by survivors with metastatic breast cancer. Supportive Care in Cancer, 2022, 30, 4291-4301.	1.0	6
7	Supporting Structured Data Capture for Patients With Cancer: An Initiative of the University of Wisconsin Carbone Cancer Center Survivorship Program to Improve Capture of Malignant Diagnosis and Cancer Staging Data. JCO Clinical Cancer Informatics, 2022, , .	1.0	0
8	Development and Implementation of an Algorithm to Guide MRI Screening in Patients With a Personal History of Treated Breast Cancer. Clinical Breast Cancer, 2021, 21, 26-30.	1.1	1
9	Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative-intent chemotherapy: A Wisconsin Oncology Network study. Cancer, 2021, 127, 801-808.	2.0	10
10	Lidocaine patches for postcesarean pain control in obese women: a pilot randomized controlled trial. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100281.	1.3	6
11	Cancer Survivorship in Women 65 Years and Older. , 2021, , 67-85.		0
12	QIM21-080: Patterns of Patient Portal Use in Patients With Cancer Who Utilized the Portal Frequently: Results From the UWCCC Survivorship Program. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, QIM21-080.	2.3	0
13	Reported Concerns and Acceptance of Information or Referrals Among Breast Cancer Survivors Seen for Care Planning Visits: Results from the University of Wisconsin Carbone Cancer Center Survivorship Program. Journal of Cancer Education, 2021, , 1.	0.6	4
14	Re-engineering Survivorship Care Plans to Support Primary Care Needs and Workflow: Results From an Engineering, Primary Care and Oncology Collaborative for Survivorship Health (EPOCH). Journal of Cancer Education, 2021, , 1.	0.6	1
15	Disparities in Telemedicine Access: A Cross-Sectional Study of a Newly Established Infrastructure during the COVID-19 Pandemic. Applied Clinical Informatics, 2021, 12, 445-458.	0.8	88
16	Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations. Cancer, 2021, 127, 3033-3034.	2.0	0
17	Patterns and predictors of cancer-specific patient health portal usage among patients with cancer: results from the UWCCC Survivorship Program. Cancer Medicine, 2021, 10, 7373-7382.	1.3	11
18	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology, 2021, 39, 2539-2551.	0.8	78

#	ARTICLE	IF	CITATIONS
19	Future research in cancer survivorship. <i>Journal of Cancer Survivorship</i> , 2021, 15, 659-667.	1.5	19
20	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	0.8	3
21	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. <i>Science Translational Medicine</i> , 2021, 13, eabd4811.	5.8	48
22	Oncologist Perspectives on Telemedicine for Patients With Cancer: A National Comprehensive Cancer Network Survey. <i>JCO Oncology Practice</i> , 2021, 17, e1318-e1326.	1.4	32
23	Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2553-2567.	1.9	35
24	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. <i>Cancer</i> , 2021, , .	2.0	3
25	Survivorship, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 676-685.	2.3	6
26	Helping Cancer Survivors Return to Work. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 662-664.	2.3	0
27	Survivorship, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 676-685.	2.3	38
28	Impact of Survivorship Care Plans and Planning on Breast, Colon, and Prostate Cancer Survivors in a Community Oncology Practice. <i>Journal of Cancer Education</i> , 2020, 35, 249-255.	0.6	16
29	Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 172-176.	2.8	23
30	Effect of a technology-supported physical activity intervention on health-related quality of life, sleep, and processes of behavior change in cancer survivors: A randomized controlled trial. <i>Psycho-Oncology</i> , 2020, 29, 1917-1926.	1.0	21
31	Addressing the needs of cancer survivors during the COVID-19 pandemic. <i>Journal of Cancer Survivorship</i> , 2020, 14, 601-606.	1.5	108
32	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020, 38, 1875-1886.	0.8	59
33	NCCN Guidelines Insights: Survivorship, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1016-1023.	2.3	64
34	Building a physical activity intervention into clinical care for breast and colorectal cancer survivors in Wisconsin: a randomized controlled pilot trial. <i>Journal of Cancer Survivorship</i> , 2019, 13, 593-602.	1.5	33
35	A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment. <i>Cancer</i> , 2019, 125, 1000-1007.	2.0	6
36	Evaluating Survivorship Care Plans for Use By Hematopoietic Stem Cell Transplant Survivors and Non-Transplant Clinicians: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S376.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1240-1246.	2.0	12
38	Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2â€“targeted therapy. <i>Cancer</i> , 2019, 125, 181-184.	2.0	1
39	The Impact of a Primary Care Education Program Regarding Cancer Survivorship Care Plans: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. <i>Journal of Cancer Education</i> , 2019, 34, 154-160.	0.6	12
40	Cancer Survivorship Care Plan Utilization and Impact on Clinical Decision-Making at Point-of-Care Visits with Primary Care: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. <i>Journal of Cancer Education</i> , 2019, 34, 252-258.	0.6	10
41	NCCN Guidelines Insights: Survivorship, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 784-794.	2.3	65
42	Adequacy of Depression Treatment in Spouses of Cancer Survivors: Findings From a Nationally Representative US Survey. <i>Journal of General Internal Medicine</i> , 2018, 33, 869-876.	1.3	6
43	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 1.	2.3	84
44	Endocrine Therapy for Breast Cancer. , 2018, , 907-923.e6.		2
45	Continued Challenges to the Adoption and Implementation of Survivorship Care Plans. <i>Journal of Oncology Practice</i> , 2018, 14, 573-576.	2.5	6
46	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Nodeâ€“Positive and High-Risk Lymph Nodeâ€“Negative Breast Cancer (E5103). <i>Journal of Clinical Oncology</i> , 2018, 36, 2621-2629.	0.8	52
47	Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1216-1247.	2.3	113
48	Moving beyond static survivorship care plans: A systems engineering approach to population health management for cancer survivors. <i>Cancer</i> , 2018, 124, 4292-4300.	2.0	25
49	A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 314-314.	0.8	5
50	Integrating survivorship care planning in radiation oncology workflow. <i>Journal of Community and Supportive Oncology</i> , 2018, 16, e66-e71.	0.1	2
51	Leveraging the electronic health record (EHR) to support survivorship care planning for bone marrow transplant (BMT) survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 57-57.	0.8	0
52	NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2548-2548.	0.8	0
53	Breast Cancer Survivor Advocacy at a University Hospital: Development of a Peer Support Program with Evaluation by Patients, Advocates, and Clinicians. <i>Journal of Cancer Education</i> , 2017, 32, 97-104.	0.6	25
54	Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1140-1163.	2.3	81

#	ARTICLE	IF	CITATIONS
55	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	3.2	66
56	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. <i>Investigational New Drugs</i> , 2017, 35, 87-94.	1.2	9
57	Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. <i>Journal of Oncology Practice</i> , 2017, 13, e486-e495.	2.5	12
58	Prospective study of work limitations in cancer patients (pts) undergoing curative chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 18-18.	0.8	1
59	A primary care education program regarding cancer survivorship care plans at the University of Wisconsin (UW).. <i>Journal of Clinical Oncology</i> , 2017, 35, 69-69.	0.8	1
60	Work-related barriers, facilitators, and strategies of breast cancer survivors working during curative treatment. <i>Work</i> , 2016, 55, 783-795.	0.6	41
61	Oncologists' perceived barriers to an expanded role for primary care in breast cancer survivorship care. <i>Cancer Medicine</i> , 2016, 5, 2198-2204.	1.3	20
62	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2659-2667.	3.2	39
63	Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. <i>Clinical Breast Cancer</i> , 2016, 16, 256-261.	1.1	19
64	Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1148-1156.	2.5	7
65	Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. <i>Cancer</i> , 2016, 122, 438-446.	2.0	35
66	Oncologists' Perspectives of Their Roles and Responsibilities During Multi-disciplinary Breast Cancer Follow-Up. <i>Annals of Surgical Oncology</i> , 2016, 23, 708-714.	0.7	35
67	Developing electronic health record (EHR)-based program to deliver survivorship care plans (SCPs) and visits at the UW Breast Center.. <i>Journal of Clinical Oncology</i> , 2016, 34, 56-56.	0.8	2
68	Evaluation of electronic care plan usage and usefulness among breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 83-83.	0.8	1
69	Completeness and accuracy of survivorship care plans (SCPs) prepared via two methods: Electronic health record (EHR) auto-population versus manual data entry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 62-62.	0.8	0
70	What is the health-related quality of life for women with metastatic breast cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 70-70.	0.8	0
71	What is the impact of treatments received for MBC on the ability to perform activities of daily living, symptom burden, and productivity?. <i>Journal of Clinical Oncology</i> , 2016, 34, e18118-e18118.	0.8	0
72	Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 958-965.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Evaluating Primary Care Providers' Views on Survivorship Care Plans Generated by an Electronic Health Record System. <i>Journal of Oncology Practice</i> , 2015, 11, e329-e335.	2.5	32
74	A multicenter phase 1 study of \hat{I}^3 -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 169-176.	1.2	32
75	Screening Magnetic Resonance Imaging Recommendations and Outcomes in Patients at High Risk for Breast Cancer. <i>Breast Journal</i> , 2015, 21, 246-253.	0.4	13
76	Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. <i>Cancer Research</i> , 2015, 75, OT2-1-06-OT2-1-06.	0.4	5
77	Abstract P1-09-15: Randomized clinical trial assessing the impact of survivorship care plans on survivor knowledge. , 2015, , .		0
78	Abstract P5-19-20: A phase I study of MK-2206 in combination with lapatinib in patients with advanced solid tumors followed by dose-expansion in advanced HER2+ breast cancer. , 2015, , .		0
79	Abstract P5-15-16: Breast cancer survivor advocacy at the University of Wisconsin Breast Center. , 2015, , .		0
80	Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score results. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 195-201.	0.1	3
81	Leveraging Electronic Health Record Systems to Create and Provide Electronic Cancer Survivorship Care Plans: A Pilot Study. <i>Journal of Oncology Practice</i> , 2014, 10, e150-e159.	2.5	45
82	Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles. <i>Science Translational Medicine</i> , 2014, 6, 229ra43.	5.8	298
83	Development and Evaluation of a Survey to Assess Survivor Knowledge Change After Survivorship Care Plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer). <i>Journal of Cancer Education</i> , 2014, 29, 270-277.	0.6	18
84	Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study. <i>Clinical Breast Cancer</i> , 2014, 14, 205-211.	1.1	8
85	Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193.) <i>J Clin Oncol</i> 2014;32:3948-3958.	0.8	118
86	Improving Quality and Safety through Human Factors Collaborations with Healthcare. <i>Proceedings of the Human Factors and Ergonomics Society</i> , 2014, 58, 728-732.	0.2	3
87	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.. <i>Journal of Clinical Oncology</i> , 2014, 32, 500-500.	0.8	38
88	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 538-538.	0.8	2
89	Oncologistsâ€™ priorities for breast cancer follow-up.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20602-e20602.	0.8	2
90	Cytochrome P450 interacting medication use in adult advanced solid tumor and phase I trial patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2591-2591.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Factors associated with loss of employment among metastatic patients.. Journal of Clinical Oncology, 2014, 32, 6585-6585.	0.8	0
92	Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy. Cancer, 2013, 119, 1140-1148.	2.0	173
93	Employment outcomes among survivors of common cancers: the Symptom Outcomes and Practice Patterns (SOAPP) study. Journal of Cancer Survivorship, 2013, 7, 191-202.	1.5	55
94	Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis. Oncologist, 2013, 18, 353-361.	1.9	67
95	Employment and retirement status of older cancer survivors compared to non-cancer siblings. Work, 2013, 46, 445-453.	0.6	8
96	Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Investigational New Drugs, 2012, 30, 1039-1045.	1.2	16
97	Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast Cancer Research and Treatment, 2012, 134, 245-251.	1.1	3
98	Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Research and Treatment, 2012, 131, 713-721.	1.1	15
99	Improving Employment Outcomes of Breast Cancer Survivors: Development of a Web-Based Educational and Decision Support Tool. Proceedings of the Human Factors and Ergonomics Society, 2011, 55, 1333-1337.	0.2	4
100	Human Factors Engineering: Targeting Systems for Change. , 2011, , 329-352.		4
101	Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience. Journal of Gastrointestinal Oncology, 2011, 2, 85-92.	0.6	9
102	Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer. Clinical Breast Cancer, 2010, 10, 471-476.	1.1	16
103	In the interest of full disclosure. Lancet Oncology, The, 2010, 11, 314-315.	5.1	0
104	Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies. Clinical Cancer Research, 2009, 15, 1460-1465.	3.2	109
105	Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptorâ€”2 tyrosine kinases used in the treatment of breast cancer. Clinical Therapeutics, 2009, 31, 2332-2348.	1.1	97
106	Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2009, 64, 45-51.	1.1	4
107	Weight gain after breast cancer diagnosis: It's complicatedâ€¦. Cancer, 0, , .	2.0	1